Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) was the target of some unusual options trading activity on Wednesday. Stock traders purchased 3,012 call options on the company. This is an increase of 4,396% compared to the average volume of 67 call options.
Large investors have recently modified their holdings of the company. Pearl River Capital LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 4th quarter worth approximately $29,000. First Mercantile Trust Co. lifted its position in shares of Madrigal Pharmaceuticals by 52.2% during the 4th quarter. First Mercantile Trust Co. now owns 624 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 214 shares during the last quarter. Advisor Group Inc. lifted its position in shares of Madrigal Pharmaceuticals by 19.3% during the 1st quarter. Advisor Group Inc. now owns 656 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 106 shares during the last quarter. Great West Life Assurance Co. Can lifted its position in shares of Madrigal Pharmaceuticals by 59.1% during the 4th quarter. Great West Life Assurance Co. Can now owns 985 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 366 shares during the last quarter. Finally, Quantamental Technologies LLC lifted its position in shares of Madrigal Pharmaceuticals by 11.6% during the 1st quarter. Quantamental Technologies LLC now owns 893 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 93 shares during the last quarter. Institutional investors and hedge funds own 60.89% of the company’s stock.
NASDAQ MDGL opened at $99.00 on Thursday. Madrigal Pharmaceuticals has a 52 week low of $89.83 and a 52 week high of $322.00. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -44.59 and a beta of 1.18.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. During the same quarter last year, the firm posted ($0.45) EPS. Equities analysts forecast that Madrigal Pharmaceuticals will post -4.35 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 18th. BidaskClub upgraded shares of Madrigal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday. ValuEngine cut shares of Madrigal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. B. Riley upgraded shares of Madrigal Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $126.00 to $128.00 in a report on Monday. Finally, HC Wainwright restated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, May 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $194.11.
WARNING: “Madrigal Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:MDGL)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2019/06/13/madrigal-pharmaceuticals-sees-unusually-large-options-volume-nasdaqmdgl.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Featured Story: Special Dividends
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.